P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

Saved in:
Bibliographic Details
Published in:HemaSphere Vol. 7; no. S2; p. 30
Main Authors: Einsele, H., Dhakal, B., Schecter, J. M., Roccia, T., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Connors, K., Qi, K., Londhe, A., Carson, R., Voelker, J., Cost, P., Valluri, S., Florendo, E., Pacaud, L., Yong, K.
Format: Journal Article
Language:English
Published: Philadelphia, PA Lippincott Williams & Wilkins 09-05-2023
Wiley
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000936268.48048.d9